NGNE logo

NGNE
Neurogene Inc

390
Mkt Cap
$471.21M
Volume
35,361.00
52W High
$37.27
52W Low
$14.65
PE Ratio
-5.94
NGNE Fundamentals
Price
$29.01
Prev Close
$29.82
Open
$29.26
50D MA
$24.43
Beta
1.61
Avg. Volume
167,846.10
EPS (Annual)
-$4.24
P/B
1.96
Rev/Employee
$0.00
$180.20
Loading...
Loading...
News
all
press releases
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the...
Business Wire·6d ago
News Placeholder
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...
Business Wire·12d ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat reports...
MarketBeat·19d ago
News Placeholder
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming...
Business Wire·20d ago
News Placeholder
Neurogene (NASDAQ:NGNE) Shares Up 0.1% - Here's What Happened
Neurogene (NASDAQ:NGNE) Stock Price Up 0.1% - What's Next...
MarketBeat·20d ago
News Placeholder
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to...
Business Wire·28d ago
News Placeholder
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...
Business Wire·1mo ago
News Placeholder
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group reduced their price target on shares of Neurogene from $200.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday...
MarketBeat·1mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm...
MarketBeat·1mo ago
<
1
2
...
>

Latest NGNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.